{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["17(11)"],"submitter":["Conti GN"],"pubmed_abstract":["<h4>Background</h4>Long-acting injectable antiretroviral therapy (LA-ART) with cabotegravir and rilpivirine (CAB + RPV) has emerged as a promising alternative to daily oral regimens for people living with HIV (PLWH), particularly those facing adherence challenges. While clinical trials have demonstrated its efficacy, real-world evidence remains limited.<h4>Methods</h4>This retrospective, multicenter study evaluated the efficacy and safety of CAB + RPV in 160 virologically suppressed PLWH across eight Italian infectious disease units. Participants received intramuscular CAB (600 mg) and RPV (900 mg) every eight weeks without an oral lead-in phase. Clinical, immunological, and biochemical parameters were assessed at baseline and after 24 weeks.<h4>Results</h4>At week 24, 96.25% of participan"],"journal":["Viruses"],"pagination":["1417"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12656754"],"repository":["biostudies-literature"],"pubmed_title":["Efficacy and Safety of Cabotegravir-Rilpivirine in PLWH: A Real-World Study."],"pmcid":["PMC12656754"],"pubmed_authors":["Cali C","Villari N","De Vito A","Fasca C","Gullotta C","Celesia BM","Pellicano GF","Montineri A","Paterno Raddusa MS","Nunnari G","Cirelli T","Iacobello C","Spampinato S","Pistara E","Venanzi Rullo E","Cacopardo B","Conti GN","Fontana Del Vecchio R","Panto G","Madeddu G","Sofia S","Mirabile A","Bruno R","Antonucci FP","Coco V","Lo Caputo S","Marino A","Franco A","Russotto Y"],"additional_accession":[]},"is_claimable":false,"name":"Efficacy and Safety of Cabotegravir-Rilpivirine in PLWH: A Real-World Study.","description":"<h4>Background</h4>Long-acting injectable antiretroviral therapy (LA-ART) with cabotegravir and rilpivirine (CAB + RPV) has emerged as a promising alternative to daily oral regimens for people living with HIV (PLWH), particularly those facing adherence challenges. While clinical trials have demonstrated its efficacy, real-world evidence remains limited.<h4>Methods</h4>This retrospective, multicenter study evaluated the efficacy and safety of CAB + RPV in 160 virologically suppressed PLWH across eight Italian infectious disease units. Participants received intramuscular CAB (600 mg) and RPV (900 mg) every eight weeks without an oral lead-in phase. Clinical, immunological, and biochemical parameters were assessed at baseline and after 24 weeks.<h4>Results</h4>At week 24, 96.25% of participan","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Oct","modification":"2026-05-19T03:14:52.452Z","creation":"2026-05-19T03:10:52.568Z"},"accession":"S-EPMC12656754","cross_references":{"pubmed":["41305440"],"doi":["10.3390/v17111417"]}}